These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35371428)

  • 41. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis.
    Mascarenhas J; Mehra M; He J; Potluri R; Loefgren C
    J Med Econ; 2020 Jul; 23(7):721-727. PubMed ID: 32159402
    [No Abstract]   [Full Text] [Related]  

  • 42. Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry.
    Góra-Tybor J; Gołos A; Mikulski D; Helbig G; Sacha T; Lewandowski K; Niesiobędzka-Krężel J; Bieniaszewska M; Wysogląd H; Grzybowska-Izydorczyk O; Seferyńska I; Sobas M; Czyżewska M; Michalska A; Sawicki W; Mazur M; Hus M; Bodzenta E; Olszewska-Szopa M; Włodarczyk M; Patkowska E; Świstek W; Jamroziak K
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e19-e26. PubMed ID: 36396583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
    Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
    Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
    Palandri F; Breccia M; Tiribelli M; Bonifacio M; Benevolo G; Iurlo A; Elli EM; Binotto G; Tieghi A; Polverelli N; Martino B; Abruzzese E; Bergamaschi M; Heidel FH; Cavazzini F; Crugnola M; Bosi C; Isidori A; Auteri G; Forte D; Latagliata R; Griguolo D; Cattaneo D; Trawinska M; Bartoletti D; Krampera M; Semenzato G; Lemoli RM; Cuneo A; Di Raimondo F; Vianelli N; Cavo M; Palumbo GA
    Hematol Oncol; 2020 Aug; 38(3):372-380. PubMed ID: 32271957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.
    Luker GD; Nguyen HM; Hoff BA; Galbán CJ; Hernando D; Chenevert TL; Talpaz M; Ross BD
    Tomography; 2016 Mar; 2(1):67-78. PubMed ID: 27213182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
    Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of Myelofibrosis: Old and New Strategies.
    Iurlo A; Cattaneo D
    Clin Med Insights Blood Disord; 2017; 10():1179545X17695233. PubMed ID: 28579852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clarifying the use of ruxolitinib in patients with myelofibrosis.
    Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
    Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.
    Harrison CN; Mesa RA; Kiladjian JJ; Al-Ali HK; Gisslinger H; Knoops L; Squier M; Sirulnik A; Mendelson E; Zhou X; Copley-Merriman C; Hunter DS; Levy RS; Cervantes F; Passamonti F; Barbui T; Barosi G; Vannucchi AM
    Br J Haematol; 2013 Jul; 162(2):229-39. PubMed ID: 23672349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-dose ruxolitinib shows effective in treating myelofibrosis.
    Yang Y; Luo H; Zheng Y; Zou Z; Niu T; Jia Y; Zhu H; Liu T; Wu Y; Chang H; Ji J; Li J; Pan L
    Ann Hematol; 2021 Jan; 100(1):135-141. PubMed ID: 33083863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treating early-stage myelofibrosis.
    Palandri F; Sabattini E; Maffioli M
    Ann Hematol; 2019 Feb; 98(2):241-253. PubMed ID: 30343328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
    Verstovsek S; Al-Ali HK; Mascarenhas J; Perkins A; Vannucchi AM; Mohan SR; Scott BL; Woszczyk D; Koschmieder S; García-Delgado R; László R; McGreivy JS; Rothbaum WP; Kiladjian JJ
    Future Oncol; 2022 Nov; ():. PubMed ID: 36416118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma.
    Ishibashi N; Maebayashi T; Aizawa T; Sakaguchi M; Abe O; Saito T; Tanaka Y
    Hematology; 2015 May; 20(4):203-7. PubMed ID: 25131182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging therapeutic options for myelofibrosis: a Canadian perspective.
    Gupta V; Foltz L; Sirhan S; Busque L; Turner AR
    Am J Blood Res; 2012; 2(3):170-86. PubMed ID: 23119228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
    McMullin MF; Harrison CN; Niederwieser D; Demuynck H; Jäkel N; Gopalakrishna P; McQuitty M; Stalbovskaya V; Recher C; Theunissen K; Gisslinger H; Kiladjian JJ; Al-Ali HK
    Exp Hematol Oncol; 2015; 4():26. PubMed ID: 26380150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
    Ellis MH; Lavi N; Mishchenko E; Dally N; Lavie D; Courevitch A; Gutwein O; Bulvik S; Braester A; Chubar E; Tavor S; Duek A; Kirgner I; Koren-Michowitz M
    Leuk Res; 2015 Aug; ():. PubMed ID: 26364797
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How I manage anemia related to myelofibrosis and its treatment regimens.
    Verstovsek S
    Ann Hematol; 2023 Apr; 102(4):689-698. PubMed ID: 36786879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.